Healthcare
Eledon Pharmaceuticals, Inc.(ELDN)
Live Price
Offline$3.92
+5.95% today
1Y Change
+44.53%
Window
Jun 25, 2025 โ Jun 24, 2026
- Market Cap
- $230.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +25.3%
- Dividend Yield
- 0.0%
Coverage: 251 bars ยท Jun 25, 2025 โ Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Eledon Pharmaceuticals, Inc. (ELDN) is a Healthcare stock with a market cap of $230.00M and listed on NASDAQ. The stock last traded around $3.92 and up 44.5% across the available one-year price window (Jun 25, 2025 โ Jun 24, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +25.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +25.3%, free cash flow -31.9% with operating margin 0.0% and ROIC -37.9%. Stock Foundry combines ELDN price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 13, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +25.3%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -5.1% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 13, 2026 | โ | +1.8% | -1.0% | -8.0% |
2026 Mar 19, 2026 | +50.0% | +1.1% | +3.9% | +39.6% |
2025 Nov 14, 2025 | +4.5% | -8.0% | -18.2% | -6.8% |
Benchmark Edge
ELDN vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
ELDN
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
ELDN Max Drawdown
-68.12%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for ELDN and SPY.
Company Overview
Eledon Pharmaceuticals, Inc.
NASDAQ Capital Market
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
- Leadership
- David-Alexandre C. Gros
- IPO Date
- Sep 17, 2014
- Employees
- 31
- Street Address
- 19900 MacArthur Boulevard
- Mailing
- Irvine, CA, 92612
- Region
- Irvine, CA, US
- Reporting Currency
- USD
- Investor Line
- 949 238 8090
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 2.1
Growth
- Revenue
- 0.0%
- EPS
- +25.3%
- Free Cash Flow
- -31.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -46.5%
- ROIC
- -37.9%
Balance Sheet
- Debt/Equity
- 0.00
- Current Ratio
- 7.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.